Hosted by Obesity Specialist Group
** Sold out***
Join Obesity Specialist Group members to critically appraise this paper. Learn how the researchers aimed to identify why GLP-1 treatment succeeds or fails for patients and what they discovered. In an exploratory study within a virtual care service, the authors examined the experiences and attitudes of individuals using GLP-1 medications (GLP-1s) for weight loss, focusing on motivators, barriers and reasons for discontinuation.
Speakers
Associate Professor Amanda Avery RD is programme lead for the MNutr and MSc Clinical Nutrition programmes at the University of Nottingham. She is also Consultant dietitian in weight management at Slimming World working in a research capacity within the Nutrition, Research & Health Policy team. Amanda’s research tends to be ‘real-world’, addresses health inequalities and looks at weight management across the life-course. She has been a BDA OSG committee member for over 20years, currently acting as research officer. She is also Chair of the EFAD Public Health specialist group supporting projects related to food insecurity.
Dr Enzo M. Battista Dowds PhD RD is a Highly Specialist Weight Management Dietitian and Research Lead at Cwm Taf Morgannwg University Health Board, Wales. He chairs the PILLAR research group and is the local PI for the LightWay study on integrated meal replacement and GLP 1–supported Tier 3 pathways. His research focuses on implementation science, polygenic obesity risk and service attrition, and he serves as ASO Wales Regional Lead and BDA Obesity Specialist Group Wales Representative).
Cost
Obesity Specialist Group member Free
Student member Free
BDA member £5
Non BDA member £10
Did you know?
BDA's new evidence-based resource for eating well while taking medicines for obesity. These are offered free of charge to the public and healthcare professionals, and developed by the BDA Obesity Specialist Group. The resources have been developed through a process involving people living with obesity who take medications for obesity, dietitians and other healthcare professionals. Find out more and download your free guide
Novo Nordisk provided a grant and Eli Lilly and Company Limited provided sponsorship to the BDA to support costs of the development and production of this obesity management resource material. Novo Nordisk and Eli Lilly and Company have had no input into or influence over the creation, development or content contained in this material.
Admin code - SLA
